25.43
0.27 (1.07%)
| Penutupan Terdahulu | 25.16 |
| Buka | 24.82 |
| Jumlah Dagangan | 23,602 |
| Purata Dagangan (3B) | 718,378 |
| Modal Pasaran | 1,657,444,096 |
| Harga / Jualan (P/S) | 1.59 |
| Harga / Buku (P/B) | 7.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2026 |
| Margin Operasi (TTM) | -373.30% |
| EPS Cair (TTM) | -3.89 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.43% |
| Nisbah Semasa (MRQ) | 6.47 |
| Aliran Tunai Operasi (OCF TTM) | -137.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -77.73 M |
| Pulangan Atas Aset (ROA TTM) | -56.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Zenas BioPharma, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -0.33 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.20% |
| % Dimiliki oleh Institusi | 74.88% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Royalty Pharma Sub-Manager, Llc | 30 Jun 2026 | 2,388,150 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |